Northern California PET Imaging Center Strides to the Forefront of the Battle Against Alzheimer's Disease
July 18, 2012 - Sacramento, CA—Northern California PET Imaging Center (NCPIC) has become among the first facilities in Northern California to offer patients the service of positron emission tomography (PET) brain imaging using the newly FDA approved agent Amyvid™, a radioactive tracer able to detect the presence of amyloid plaques in the brain. This process is a critical component in determining if a patient has the pathology of Alzheimer’s Disease (AD).
FDA Approves Amyvid™ (Florbetapir F 18 Injection) for Use in Patients Being Evaluated for Alzheimer's Disease and Other Causes of Cognitive Decline
Amyvid is the first and only radioactive diagnostic agent approved for PET imaging of beta-amyloid neuritic plaques in the living brain
INDIANAPOLIS, April 6, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced the U.S. Food and Drug Administration (FDA) approval of Amyvid™, a radioactive diagnostic agent indicated for brain imaging of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline. Amyvid binds to amyloid plaques, a hallmark characteristic of Alzheimer's Disease,,, and is detected using PET scan images of the brain.
Northern California PET Imaging Center Steven W. Falen, MD, PhD Receives 2011 Best of Sacramento Award
U.S. Commerce Association’s Award Plaque Honors the Achievement
New York, NY - December 7, 2011 - Northern California PET Imaging Center Steven W. Falen, MD, PhD has been selected for the 2011 Best of Sacramento Award in the Radiology Physicians category by the U.S. Commerce Association (USCA).
New Public-Private Partnership to Create Research, Training and Commercial Manufacturing Hub for Radiopharmaceuticals at UC Davis in Sacramento
Sacramento, Calif. - October 10, 2011 - UC Davis Health System, PETNET Solutions Inc., a wholly owned subsidiary of Siemens Medical Solutions USA, Inc., and Northern California PET Imaging Center (NCPIC) announced today that they will partner to establish a facility on the university’s Sacramento campus for research and training in radiochemistry and for the commercial production of radiopharmaceutical products used in positron emission tomography (PET) scans - an imaging technique that provides molecular information important for diagnosing disease and conducting clinical research.
Innovative PET/CT Scanner Installed in Sacramento
Sacramento, CA - November 2010 - Northern California PET Imaging Center, a not-for-profit, community benefit organization, announces the installation of the newest innovation in PET/CT scanners. Located in midtown Sacramento, this scanner offers patients the highest quality PET/CT scans possible in half the time without sacrificing quality, and yet, able to reduce their radiation exposure.
SNM Calls CMS PET Scan Decision a Major Benefit for Cancer Patients
National Oncologic PET Registry Provided Overwhelming Evidence of PET’s Value
Reston, Va. - SNM applauds today's decision by the Centers for Medicare and Medicaid Services (CMS) to expand coverage of positron emission tomography (PET) scans in the initial treatment strategy of patients with cancer. This decision was based, in large part, on compelling clinical evidence of the effectiveness of PET for cancer management and treatment contained in a comprehensive study known as the National Oncologic PET Registry (NOPR).
New Diagnostic Criteria and Guidelines for Alzheimer's Disease
Three expert international workgroups convened by the Alzheimer's Association and the National Institute on Aging (NIA) have issued the first new criteria and guidelines to diagnose Alzheimer's disease in 27 years. The new guidelines update, refine and broaden widely used guidelines published in 1984 by the Alzheimer's Association (then known as the Alzheimer's Disease and Related Disorders Association) and the National Institute of Neurological and Communicative Disorders and Stroke (now known as the National Institute of Neurological Disorders and Stroke).
These updated criteria and guidelines result from work that began two years ago, when more than 40 Alzheimer's researchers and clinicians from around the globe began in-depth review of the original criteria to decide how they might be improved by incorporating research advances from the last three decades.